The lymphocyte function-associated antigen-1 (LFA-1) (also known as CD11a/CD18 and αLβ2), is just one of many integrins in the human body, but its significance is derived from its exclusive presence in leukocytes. In this review, we summarize the studies relating LFA-1 and its major ligand ICAM-1 (or CD54) with cancer, through the function of lymphocytes and myeloid cells on tumor cells. We consider how LFA-1 mediates the interaction of leukocytes with tumors and the role of ICAM-1 in tumor dynamics, which can be independent of its interaction with LFA-1. We also offer a more detailed examination of the role of LFA-1 within B-cell chronic lymphocytic leukemia. Finally, we discuss the role that exosomes harboring LFA-1 play in tumor growth and metastasis.
1 February 2005 in Seminars in Cell & Developmental Biology
Objective: Cannabinoids are able to reduce tumor growth in xenograft models, but their therapeutic potential as anti-cancer drugs in humans is unclear yet. In vitro studies of the effect of cannabinoids on cancer cells are often carried out in absence of serum or in low serum concentration (i.e. 0.5% serum), conditions that limit cellular growth and therefore can increase the response of cells to additional challenges such as the presence of cannabinoids. However, the tumor microenvironment can be teaming with growth factors. In this study we assessed the viability and proliferation of cancer cells treated with cannabidiol in presence of a serum concentration that commonly sustains cell growth (10% serum). Results: The results show that cannabidiol exerts a markedly different effect on the viability of the human HT-29 cancer cell line when cultured in presence of 0.5% serum in comparison to 10% serum, displaying a cytotoxic effect only in the former situation. In presence of 10% serum, no inhibitory effect of cannabidiol on DNA replication of HT-29 cells was detected, and a weak inhibition was observed for other cancer cell lines. These results indicate that the effect of cannabidiol is cell context-dependent being modulated by the presence of growth factors.
Summary: T cells express the heparan sulphate proteoglycans syndecan‐2 and syndecan‐4. Syndecan‐4 plays a T‐cell inhibitory role; however, the function of syndecan‐2 is unknown. In an attempt to examine this function, syndecan‐2 was expressed constitutively in Jurkat T cells. Interestingly, the expression of syndecan‐2 decreased the surface levels of T‐cell receptor (TCR)/CD3 complex, concomitant with intracellular retention of CD3ε and partial degradation of the TCR‐ζ chain. Immunofluorescence microscopy revealed that intracellular CD3ε co‐located with Rab‐4 endosomes. However, the intracellular pool of CD3ε did not recycle to the cell surface. The lower TCR/CD3 surface levels caused by syndecan‐2 led to reduced TCR/CD3 responsiveness. We show that the cytosolic PDZ‐binding domain of syndecan‐2 is not necessary to elicit TCR/CD3 down‐regulation. These results identify a previously unrecognized means of controlling surface TCR/CD3 expression by syndecan‐2.
The superantigen toxic shock syndrome toxin (TSST)-1 can induce tumor necrosis factor (TNF)-α expression in T cells and monocytes, through different signaling pathways. We have stimulated peripheral blood mononuclear cells with TSST-1 and found that the major cell producers of TNF-α as detected by cytofluorimetry and immunocytochemistry were CD4+ T lymphocytes. The expression of TNF-α by CD4+ T cells can be inhibited by either, wortmannin (WN) or LY 294002, two phosphatidylinositol 3-kinase (PI 3-K) inhibitors. The inhibitory effect is not transcriptional as WN does not change the mRNA steady state of TNF-α at any of the concentrations tested and LY 294002 when preincubated with mononuclear cells at its median inhibitory concentration (IC50 = 1.4 μM) significantly inhibited the expression of TNF-α but not its mRNA. Immunoprecipitation of pulse-labeled intracellular TNF-α showed a specific decrease in the synthesis of this cytokine on cells treated with PI 3-K inhibitors. The p38 mitogen-activated protein kinase (MAPK) is involved in control of TNF-α translation in human macrophages. In T cells, we have found that the p38 MAPK inhibitor SB 203580 significantly decreased the secretion of TNF-α but not its mRNA. In addition, the combined use of WN and SB 203580 had an additive inhibitory effect on secretion of TNF-α. Therefore, both PI 3-K and p38 MAPK signaling pathways control TNF-α production in T cells.